Yang Chunhua, Gu Jieruo, Rihl Markus, Baeten Dominique, Huang Feng, Zhao Miansong, Zhang Hanwei, Maksymowych Walter P, De Keyser Filip, Veys Eric M, Yu David T Y
University of California Los Angeles, USA.
Arthritis Rheum. 2004 Oct 15;51(5):691-9. doi: 10.1002/art.20696.
To assess the usefulness of measuring serum matrix metalloproteinase 3 (MMP-3) and macrophage colony-stimulating factor (M-CSF) in patients with ankylosing spondylitis (AS).
Serum levels of MMP-3 and M-CSF were measured in AS patients who did and did not receive infliximab treatment. These were compared with those of 28 healthy subjects.
In the group of AS patients not treated with biologics, both M-CSF and MMP-3 correlated with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) values, but not with each other. Logistic regression analysis showed that MMP-3 values were high in those with severely active disease. Infusions of infliximab in AS patients led to a significant decrease in the values of the BASDAI as well as the serum MMP-3, but no change in the serum M-CSF values.
MMP-3 and M-CSF are potentially useful markers of AS disease activity.
评估检测强直性脊柱炎(AS)患者血清基质金属蛋白酶3(MMP - 3)和巨噬细胞集落刺激因子(M - CSF)的作用。
检测接受和未接受英夫利昔单抗治疗的AS患者血清中MMP - 3和M - CSF水平,并与28名健康受试者的水平进行比较。
在未接受生物制剂治疗的AS患者组中,M - CSF和MMP - 3均与巴斯强直性脊柱炎疾病活动指数(BASDAI)值相关,但彼此之间无相关性。逻辑回归分析显示,疾病严重活动者的MMP - 3值较高。AS患者输注英夫利昔单抗导致BASDAI值以及血清MMP - 3显著降低,但血清M - CSF值无变化。
MMP - 3和M - CSF可能是AS疾病活动的有用标志物。